Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus GRISACTIN ULTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus GRISACTIN ULTRA.
EXTINA vs GRISACTIN ULTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Griseofulvin binds to tubulin and disrupts microtubule function, inhibiting fungal cell division and nucleic acid synthesis.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
500 mg orally once daily or 250 mg orally twice daily; for severe infections, 500 mg twice daily or 250 mg three times daily. Maximum daily dose: 1 g. Administer with or after meals.
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal elimination half-life ranges from 6.5 to 9 hours (mean ~7.5 hours) in patients with normal hepatic function; prolonged in hepatic impairment.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; approximately 30-50% of a dose is eliminated in feces as metabolites, with minor biliary excretion.
Category C
Category C
Antifungal
Antifungal